The US FDA approves a gene therapy targeting sensorineural hearing loss before 2030.

Question

Six frontier AI models put this at 53% by 19 Sept 2031. Full reasoning from every model.

WillHappen.ai · Accepted Answer

53% — the median of 6 frontier models, resolving by 2031-09-19.

Answer

Gemini (Google): 74% — Success hinges on Regeneron and Eli Lilly converting small otoferlin Phase 1/2 cohorts into pivotal data without durable toxicity issues. Otoferlin (OTOF) therapies hold RMAT and Orphan status, enabling accelerated approval on small patient pools by late 2028 or 2029. Phase 1/2 data demonstrated dramatic, bilateral auditory gains, giving regulators overwhelming efficacy endpoints rarely seen in SNHL. A failure of vector redosing durability or unexpected surgical delivery complications into the cochlea would rapidly derail timelines.

Answer

Claude (Anthropic): 42% — Whether otoferlin gene therapy (Regeneron/Decibel, Akouos/Eli Lilly) clears pivotal trials and FDA review by 2030. Multiple OTOF gene therapy programs (Akouos/Lilly, Decibel/Regeneron, Sensorion) showed strong early efficacy in 2023-2024 trials, ahead of typical rare-disease… Pivotal trials, BLA filing, and FDA review typically take 3-5 years from early success, putting a 2028-2030 approval plausible but not assured given small patient pools… OTOF-only mutation covers a narrow population, so a broader 'sensorineural hearing loss' therapy is less likely than an OTOF-specific approval; any pivotal trial failure…

Answer

GPT (OpenAI): 63% — Whether early pediatric hearing-restoration results translate into durable, registrational safety and efficacy data fast enough. Eli Lilly/Akous and Regeneron/Decibel programs must complete dose, durability, and pivotal studies, then file a BLA before 2030. FDA has no approved inner-ear gene therapy; AAV products have cleared in other rare diseases, but follow-up and manufacturing often extend timelines. A rapid pivotal path for OTOF after replicated speech/hearing gains would raise odds most; serious vestibular, immune, or durability signals would cut them.

Answer

Grok (xAI): 72% — Pivotal data and BLA from OTOF programs (Lilly/Regeneron) must reach FDA by ~2028. 2024 OTOF gene-therapy readouts already showed hearing restoration in infants; rare-disease gene therapies often skip large Phase 3s. From Sept 2026, 3+ years remain for 12–18-month follow-up, BLA, and 10-month FDA review—matching Luxturna/Zolgensma timelines. Safety signals or manufacturing delays would drop odds most; otherwise base rate for genetic-deafness GT exceeds typical neurology programs.

Answer

DeepSeek (DeepSeek): 22% — Whether an otoferlin gene therapy clears an FDA BLA before 2030, not whether the science works. Regeneron's DB-OTO and Decibel's DB-OTO/DB-OTO-like programs are the frontrunners, but both are still in Phase 1/2 with no pivotal trial started as of late 2026. A BLA needs a completed pivotal trial plus 6-12 months of FDA review, so a Phase 3 must begin by roughly 2028 to make a 2030 approval. Precedent is thin: Zolgensma and Luxturna took years from early data to approval, and no hearing-loss gene therapy has yet entered registrational trials.

Answer

Qwen (Alibaba): 34% — Otoferlin gene therapy has strong Phase I/II data but needs a pivotal trial or accelerated pathway to clear FDA by 2030. Regeneron/DB-OTO and Eli Lilly/Akouos both reported positive Phase I/II results in 2024, but neither has completed a registrational trial as of mid-2026. FDA accelerated approval for rare pediatric conditions is possible but requires a confirmatory endpoint; the agency has not yet signaled a clear path for hearing-loss… Base rate for rare-disease gene therapies from first-in-human data to approval is ~5-7 years; this case sits slightly above base due to strong early efficacy signals but…

The US FDA approves a gene therapy targeting sensorineural hearing loss before 2030.

The US FDA approves an anti-aging therapeutic indicated specifically to slow biological aging before 2035.

A fully lab-grown solid organ is successfully transplanted into a human patient in a clinical trial before 2032.

A gene editing therapy for herpes simplex virus enters Phase 3 clinical trials before 2029.

The US FDA approves an in vivo CRISPR gene editing therapy before January 1, 2028.